Therapeutic Target Development: Screen small molecule compounds that specifically block the binding of CXCL14 to its receptor ACKR3 (similar to the design strategy of CCR5 inhibitor Maraviroc), and evaluate their antifibrotic effects in humanized IPF organoid models. This evidence concerns the gene CXCL14 and idiopathic pulmonary fibrosis.